Potiga Whizzes Through Advisory Panel Review With Thorough Risk Management Plan
This article was originally published in The Pink Sheet Daily
Executive Summary
Despite urinary retention and a number of other concerning side effects, GlaxoSmithKline and Valeant's epilepsy drug ezogabine carries the day, based in part on a pledge to do a post-market observational safety study.
You may also be interested in...
GSK/Valeant's Potiga Gets REMS, Needs DEA Classification For Launch
The anti-seizure drug should be available by the end of the year following approval June 10.
GSK/Valeant's Potiga Gets REMS, Needs DEA Classification For Launch
The anti-seizure drug should be available by the end of the year following approval June 10.
GSK, Valeant Willing To Exclude Some Epilepsy Patients From Potiga Market
GlaxoSmithKline and Valeant Pharmaceuticals appear willing to sacrifice a part of the target market for their anti-epileptic drug Potiga (ezogabine), as well as implement an extensive Risk Evaluation and Mitigation Strategy, in order to gain approval